Design, synthesis, and docking of novel thiazolidine‐2,4‐dione multitarget scaffold as new approach for cancer treatment

Novel thiazolidine-2,4-diones have been developed and estimated as conjoint inhibitors of EGFRT790M and VEGFR-2 against HCT-116, MCF-7, A549, and HepG2 cells. Compounds 6a, 6b, and 6c were known to be the dominant advantageous congeners against HCT116 (IC50  = 15.22, 8.65, and 8.80 µM), A549 (IC50  = 7.10, 6.55, and 8.11 µM), MCF-7 (IC50  = 14.56, 6.65, and 7.09 µM) and HepG2 (IC50  = 11.90, 5.35, and 5.60 µM) mass cell lines, correspondingly. Although compounds 6a, 6b, and 6c disclosed poorer effects than sorafenib (IC50  = 4.00, 4.04, 5.58, and 5.05 µM) against the tested cell sets, congeners 6b and 6c demonstrated higher actions than erlotinib (IC50  = 7.73, 5.49, 8.20, and 13.91 µM) against HCT116, MCF-7 and HepG2 cells, yet lesser performance on A549 cells. The hugely effective derivatives 4e-i and 6a-c were inspected versus VERO normal cell strains. Compounds 6b, 6c, 6a, and 4i were found to be the most effective derivatives, which suppressed VEGFR-2 by IC50  = 0.85, 0.90, 1.50, and 1.80 µM, respectively. Moreover, compounds 6b, 6a, 6c, and 6i could interfere with the EGFRT790M performing strongest effects with IC50  = 0.30, 0.35, 0.50, and 1.00 µM, respectively. What is more, 6a, 6b, and 6c represented satisfactory in silico computed ADMET profile.

[1]  Riham F. George,et al.  Exploration of thiazolidine‐2,4‐diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations , 2022, Archiv der Pharmazie.

[2]  F. Ahmed,et al.  In silico ADMET, docking, anti-proliferative and antimicrobial evaluations of ethanolic extract of Euphorbia dendroides L. , 2022, South African Journal of Botany.

[3]  A. Deep,et al.  Thiazolidin-2,4-Dione Scaffold: An Insight into Recent Advances as Antimicrobial, Antioxidant, and Hypoglycemic Agents , 2022, Molecules.

[4]  Wagdy M. Eldehna,et al.  Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies , 2022, Journal of enzyme inhibition and medicinal chemistry.

[5]  Riham F. George,et al.  Design, synthesis, in silico docking, ADMET and anticancer evaluations of thiazolidine-2,4-diones bearing heterocyclic rings as dual VEGFR-2/EGFRT790M tyrosine kinase inhibitors , 2022, RSC advances.

[6]  Khaled El-Adl,et al.  Design, synthesis, anticancer, and docking of some S‐ and/or N‐heterocyclic derivatives as VEGFR‐2 inhibitors , 2021, Archiv der Pharmazie.

[7]  C. Mascaux,et al.  Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring , 2021, Cancers.

[8]  I. Eissa,et al.  Phthalazine‐based VEGFR‐2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations , 2021, Archiv der Pharmazie.

[9]  S. Salama,et al.  Design, synthesis, molecular docking and in silico ADMET profile of pyrano[2,3-d]pyrimidine derivatives as antimicrobial and anticancer agents. , 2021, Bioorganic chemistry.

[10]  Khaled El-Adl,et al.  Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors. , 2021, Bioorganic chemistry.

[11]  Hu Liu,et al.  Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments. , 2021, Bioorganic & medicinal chemistry letters.

[12]  G. Simone,et al.  Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role , 2020, Frontiers in Cell and Developmental Biology.

[13]  S. Dixit,et al.  Discovery of Rhodanine and Thiazolidinediones as Novel Scaffolds for EGFR Inhibition: Design, Synthesis, Analysis and CoMSIA Studies , 2020, Polycyclic Aromatic Compounds.

[14]  X. Le,et al.  Dual EGFR/VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  I. Eissa,et al.  Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme. , 2020, Bioorganic chemistry.

[16]  J. Cui,et al.  Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments , 2020, Journal of Cancer Research and Clinical Oncology.

[17]  J. Molina,et al.  Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. , 2019, Mayo Clinic proceedings.

[18]  K. Saied,et al.  Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. , 2019, Bioorganic chemistry.

[19]  V. Kulkarni,et al.  Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR Inhibitors: Medicinal Chemistry Perspective , 2019, Medicine in Drug Discovery.

[20]  Qingsong Liu,et al.  Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC. , 2017, European journal of medicinal chemistry.

[21]  Huabei Zhang,et al.  Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro. , 2017, European journal of medicinal chemistry.

[22]  F. Halaweish,et al.  Design and synthesis of pyrazolo[3,4-d]pyrimidines: Nitric oxide releasing compounds targeting hepatocellular carcinoma. , 2017, Bioorganic & medicinal chemistry.

[23]  Mamdouh M. Ali,et al.  1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation. , 2016, European journal of medicinal chemistry.

[24]  V. Gandin,et al.  Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N’-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily , 2015, Scientific Reports.

[25]  Rui M. V. Abreu,et al.  Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors. , 2015, Bioorganic & medicinal chemistry.

[26]  M. Clausen,et al.  FDA-approved small-molecule kinase inhibitors. , 2015, Trends in pharmacological sciences.

[27]  Douglas E. V. Pires,et al.  pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.

[28]  S. Knapp,et al.  Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? , 2014, ACS chemical biology.

[29]  F. Totzke,et al.  Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. , 2014, European journal of medicinal chemistry.

[30]  A. Dahan,et al.  Oral Delivery of Lipophilic Drugs: The Tradeoff between Solubility Increase and Permeability Decrease When Using Cyclodextrin-Based Formulations , 2013, PloS one.

[31]  Jianping Chen,et al.  Dietary Compound Isoliquiritigenin Inhibits Breast Cancer Neoangiogenesis via VEGF/VEGFR-2 Signaling Pathway , 2013, PloS one.

[32]  Yoshinori Hoshino,et al.  Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer Cells , 2013, PloS one.

[33]  Satoru Takahashi,et al.  Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. , 2011, Biological & pharmaceutical bulletin.

[34]  H. Jaafar,et al.  Breast Tumor Angiogenesis and Tumor-Associated Macrophages: Histopathologist's Perspective , 2011, Pathology research international.

[35]  Kyungik Lee,et al.  Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. , 2010, European journal of medicinal chemistry.

[36]  Christopher Hulme,et al.  The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796. , 2010, Bioorganic & medicinal chemistry.

[37]  K. Menon,et al.  Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro. , 2007, Fertility and sterility.

[38]  Irene Manrique,et al.  Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model , 2010, BMC Cancer.

[39]  Ji-Xia Ren,et al.  Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2. , 2009, Journal of molecular graphics & modelling.

[40]  R. Talanian,et al.  Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. , 2006, Analytical biochemistry.

[41]  N. Benoiton,et al.  The preparation and reactions of mixed anhydrides of N-alkoxycarbonylamino acids , 1987 .

[42]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.